Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on the shares. Although flat year-over-year sales in ...

Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ARCT-2304, designed for active immunization to protect ...

The two brightest nighttime stars available in the Minnesota and Wisconsin sky are Sirius and Arcturus. April is the only month of the year we can enjoy both of them at the same time in the early ...